Recruiting
Phase 1
Phase 2

Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)

Sponsor:

Prevail Therapeutics

Code:

NCT04408625

Conditions

Frontotemporal Dementia

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

LY3884963

Methylprednisolone

Optional Sirolimus

Optional Prednisone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information